Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.35 |
| ▸ | HTR3A | P46098 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL4466442 | 0.99 | KDM1A (0.42) | KDM1AALOX5APIDO1METAP2GRIN2B | |
| SCHEMBL5221907 | 0.89 | GRM5 (0.34) | KDM1AALOX5APHCRTR1HCRTR2 | |
| Bromide SCHEMBL4469519 | 0.88 | ALOX5AP (0.33) | KDM1AALOX5APHCRTR1HCRTR2 | |
| SCHEMBL4466231 | 0.86 | HPGDS (0.41) | IDO1 | |
| SCHEMBL4463296 | 0.85 | HSD11B1 (0.40) | HCRTR1HCRTR2 | |
| Bromide SCHEMBL4480660 | 0.85 | HPGDS (0.41) | IDO1HCRTR1HCRTR2 | |
| SCHEMBL2678305 | 0.85 | KDM1A (0.47) | KDM1AHTR3AMEN1KMT2A | |
| Bromide SCHEMBL4461513 | 0.84 | CHRNA7 (0.39) | KDM1AALOX5APKMT2A | |
| Bromide SCHEMBL4471147 | 0.84 | HSD11B1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL2678219 | 0.83 | HPGDS (0.43) | IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465893-B1 | DERIVATIVES OF 5-(PYRIDIN-3-YL)-1-AZABICYCLO (3.2.1) OCTANE, THE PREPARATION THEREOF AND THE APPLICATION OF SAME IN THERAPEUTICS | SANOFI AVENTIS (FR) | 2007-02-28 | — | — | EP | claimed |
| US-7223750-B2 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1]octane, the preparation thereof and the application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-29 | — | — | US | disclosed |
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | SANOFI (FR) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020568-A1 | Derivatives of 5-(pyridin-3-yl)-1-azabicyclo[3.2.1] octane, the preparation thereof and the application of same in therapeutics | PAICS, NAT1, TPMT | KDM1A 866/4885ALOX5AP 878/4885IDO1 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.